Featured Stories

Guangzhou Magpie Pharmaceuticals announced the clinical trials of MN-08, a treatment for Idiopathic Pulmonary Artery Hypertension (IPAH).  IPAH is a progressive disease that affects the precapillary pulmonary vasculature.  IPAH is a rare and fatal disease which has a high mortality rate. During the collaboration between Magpie Pharmaceuticals and Medicilon, Medicilon completed the research and developmentRead more

In 2019, Medicilon has had an extraordinary year. The steadily developing Medicilon made a huge accumulation in 2019 and achieved a qualitative leap.  Let us look back on the moments of glory and Extraordinary “2 0 1 9”. 2 – Double Happiness I Listed on Sci-Tech Innovation Board in Shanghai On Nov. 5th 2019, ShanghaiRead more

During the Spring Festival, China has been facing a difficult time as the coronavirus spread all over the country.  In order to stop the coronavirus, we look forward to the effective prevention and control to stop the outbreak of the virus and the symptomatic treatment.  We also hope the anti-virus vaccines and drugs could beRead more

Medicilon was awarded “2019 Excellent Listed Enterprise” for its remarkable innovation and advances in the year 2019, at ZJ Science City Annual Event in Jan. 10th, 2020. This award showcased the huge progress Medicilon has made since going public in 2019 and would inspire Medicilon to keep the momentum in 2020 and achieve bigger success.Read more

Warmest Holiday Greetings to you and your families from Medicilon! As the end of year is approaching, we would like to express our sincere gratitude for all your kind business.  Thank you so much for all your trust and support! We have made great strides at Medicilon in 2019: We listed an IPO on Sci-TechRead more